erythrocyte destruction
Recently Published Documents


TOTAL DOCUMENTS

61
(FIVE YEARS 1)

H-INDEX

19
(FIVE YEARS 0)

Author(s):  
Annette M. Nti ◽  
Felix Botchway ◽  
Hassana Salifu ◽  
Juan Carlos Cespedes ◽  
Adriana Harbuzariu ◽  
...  

In malaria endemic countries, anemia in pregnant women occurs as a result of erythrocyte destruction by Plasmodium infections and other causes including malnutrition. Iron supplementation is recommended as treatment of iron-deficiency anemia. Erythrocyte destruction results in increased release of cytotoxic free heme that is scavenged by haptoglobin (Hp), hemopexin (Hx) and heme oxygenase-1 (HO-1). Paradoxically, iron supplementation in pregnant women has been reported to enhance parasitemia and increase levels of free heme. The relationship between free heme, heme scavengers, and birth outcomes has not been investigated, especially in women who are on iron supplementation. We hypothesized that parasite-infected pregnant women on routine iron supplementation have elevated heme and altered expression of heme scavengers. A cross-sectional study was conducted to determine the association between plasma levels of free heme, HO-1, Hp, Hx, and malaria status in pregnant women who received routine iron supplementation and their birth outcomes. Heme was quantified by colorimetric assay and scavenger protein concentration by ELISA. We demonstrated that iron-supplemented women with asymptomatic parasitemia had increased free heme (mean 75.6 µM; interquartile range [IQR] 38.8–96.5) compared with nonmalaria iron-supplemented women (mean 34.9 µM; IQR 17.4–43.8, P < 0.0001). Women with preterm delivery had lower levels of Hx (mean 656.0 µg/mL; IQR 410.9–861.3) compared with women with full-term delivery (mean: 860.9 µg/mL; IQR 715.2–1055.8, P = 0.0388). Our results indicate that iron supplementation without assessment of circulating levels of free heme and heme scavengers may increase the risk for adverse pregnancy outcomes.


2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Sylwia Sulimiera Michalak ◽  
Anna Olewicz-Gawlik ◽  
Joanna Rupa-Matysek ◽  
Edyta Wolny-Rokicka ◽  
Elżbieta Nowakowska ◽  
...  

AbstractAutoimmune hemolytic anemia (AIHA) is an acquired, heterogeneous group of diseases which includes warm AIHA, cold agglutinin disease (CAD), mixed AIHA, paroxysmal cold hemoglobinuria and atypical AIHA. Currently CAD is defined as a chronic, clonal lymphoproliferative disorder, while the presence of cold agglutinins underlying other diseases is known as cold agglutinin syndrome. AIHA is mediated by autoantibodies directed against red blood cells (RBCs) causing premature erythrocyte destruction. The pathogenesis of AIHA is complex and still not fully understood. Recent studies indicate the involvement of T and B cell dysregulation, reduced CD4+ and CD25+ Tregs, increased clonal expansions of CD8 + T cells, imbalance of Th17/Tregs and Tfh/Tfr, and impaired lymphocyte apoptosis. Changes in some RBC membrane structures, under the influence of mechanical stimuli or oxidative stress, may promote autohemolysis. The clinical presentation and treatment of AIHA are influenced by many factors, including the type of AIHA, degree of hemolysis, underlying diseases, presence of concomitant comorbidities, bone marrow compensatory abilities and the presence of fibrosis and dyserthropoiesis. The main treatment for AIHA is based on the inhibition of autoantibody production by mono- or combination therapy using GKS and/or rituximab and, rarely, immunosuppressive drugs or immunomodulators. Reduction of erythrocyte destruction via splenectomy is currently the third line of treatment for warm AIHA. Supportive treatment including vitamin supplementation, recombinant erythropoietin, thrombosis prophylaxis and the prevention and treatment of infections is essential. New groups of drugs that inhibit immune responses at various levels are being developed intensively, including inhibition of antibody-mediated RBCs phagocytosis, inhibition of B cell and plasma cell frequency and activity, inhibition of IgG recycling, immunomodulation of T lymphocytes function, and complement cascade inhibition. Recent studies have brought about changes in classification and progress in understanding the pathogenesis and treatment of AIHA, although there are still many issues to be resolved, particularly concerning the impact of age-associated changes to immunity.


2020 ◽  
Vol 30 (6) ◽  
pp. 522-524
Author(s):  
Marina C. A. V. Conrado ◽  
Guilherme S. V. C. Fonseca ◽  
Marcia R. Dezan ◽  
Fernanda R. Mendes ◽  
Débora T. Hamasaki ◽  
...  

2017 ◽  
Vol 89 ◽  
pp. 203 ◽  
Author(s):  
Inge Baas ◽  
Edimara S. Reis ◽  
Daniel Ricklin ◽  
John D. Lambris ◽  
Masja de Haas ◽  
...  

2015 ◽  
Vol 6 (1) ◽  
Author(s):  
K.J. Ahlqvist ◽  
S. Leoncini ◽  
A. Pecorelli ◽  
S.B. Wortmann ◽  
S. Ahola ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document